Key terms
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NERV news
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 27
11:05am ET
Hold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial Constraints
Feb 27
9:39am ET
Minerva trading resumes
Feb 27
9:34am ET
Minerva trading halted, volatility trading pause
Feb 27
8:13am ET
Minerva receives complete response letter from FDA for NDA for roluperidone
Feb 23
6:31am ET
Analysts Offer Insights on Healthcare Companies: Minerva Neurosciences (NERV), Citius Pharmaceuticals (CTXR) and Amylyx Pharmaceuticals Inc (AMLX)
No recent news articles are available for NERV
No recent press releases are available for NERV
NERV Financials
Key terms
Ad Feedback
NERV Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NERV Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range